'Massive Improvement' With Second-Line Enhertu in HER2+ Breast Cancer

(MedPage Today) -- The recently approved antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) was clearly more effective in treating metastatic HER2-positive breast cancer than standard-of-care trastuzumab emtansine (T-DM1; Kadcyla)...